Home Oncology Breast Cancer FDA approves Ibrance for postmenopausal women with metastatic breast cancer

FDA approves Ibrance for postmenopausal women with metastatic breast cancer

On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here